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A B S T R A C T
While substantial progress over the past 60 years has enabled a greater proportion of persons with
epilepsy (PWE) to live without seizures and treatment-related side effects, numerous challenges in the
diagnosis, treatment and social management of epilepsy remain to be solved over the next 60 years so
that no person with epilepsy is limited by any aspect of the condition. This achievement is within our
reach, butwill require professional and lay epilepsy organisations towork closely together to ensure that
clinical, scientiﬁc and sociological advances aremade and applied to themedical and social management
of epilepsy.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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journal homepage: www.e lsev ier .com/ locate /yse izAs described elsewhere in this special issue, substantial progress
has been made over the past 60 years with regard to characterizing
the basic pathophysiology of epilepsy, developing new therapies,
recognizing the psychiatric comorbidities of epilepsy, identifying
determinants of felt and enacted stigma, and disseminating
information about epilepsy to professionals and the lay public.
Considerable work remains, however. Epilepsy cannot be
prevented and cures are quite limited. Nearly half of all persons
with epilepsy (PWE) do not have an identiﬁable underlying cause.
The majority of PWE with access to treatments continue to have
seizures or troublesome side effects. Depression and anxiety are
under-recognized and undertreated. Stigma and discrimination
limit the life experiences of many PWE. Epilepsy is increasingly
impacting more elderly persons as that portion of the population
increases at a faster rate than younger persons, especially in
developed countries. Finally, and alarmingly, an estimated three
out of four persons with epilepsy globally do not receive evidence-
based therapy, primarily because of limited access to medical care
and the unaffordable costs of treatment.
These problems and several others have been highlighted by
the author in this article together with suggested targets for
improvement in the clinical and social management of epilepsy
over the next 60 years. Other authors would likely, and equally as
reasonably, have emphasized different unmet needs and hence
recommended a different set of priorities for moving forward.* Tel.: +1 617 667 4460; fax: +1 617 667 7919.
E-mail address: sschacht@bidmc.harvard.edu.
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doi:10.1016/j.seizure.2010.10.0241. What are the problems with the clinical and social
management of epilepsy today?
Diagnosis. The diagnosis of epilepsy today is largely based on
clinical grounds and supported by diagnostic tests, primarily
electroencephalography (EEG) and neuroimaging studies.1 Not-
withstanding signiﬁcant advances in EEG and neuroimaging
techniques, there remain multiple diagnostic challenges to the
evaluation of persons at risk for developing epilepsy as well as
those with epilepsy. At the present time, we are unable to
 accurately identify persons before they manifest seizures
 determine which patients, having had one seizure, are certain to
have further seizures and which patients will deﬁnitely not
 specifywhichantiepilepticdrug(AED)orAEDcombination ismost
likely to effectively and safely prevent seizures in a given PWE
 avoid potentially life-threatening, idiosyncratic reactions to
AEDs, with the notable exception of carbamazepine2
 decide when AEDs can be discontinued without risk of seizure
recurrence
Because diagnostic tests to support these everyday clinical
decisions are not available, patients may be unnecessarily exposed
to AEDs, whether to prevent a ﬁrst seizure or subsequent seizures,
or may unnecessarily suffer from seizures and the associated
physical and psychiatric complications as well as the social
ramiﬁcations.
Another limitation at present is that many epilepsy comorbid-
ities, such as mood or psychotic disorders, reproductive endocrine
disorders and nonepileptic attack disorder (also called psychogenicvier Ltd. All rights reserved.
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prior to or soon after becoming clinically symptomatic. Conse-
quently, diagnosis and initiation of treatment for these conditions
is often delayed months to years.3,4
A fundamental diagnostic problem pertains to measurement of
seizures – the primary symptom of epilepsy. Indeed, the treatment
of PWE and the assessment of new interventionswith clinical trials
are based on quantifying seizure frequency and severity. Patient
and caregiver self-report, for example with a diary, is the typical
means for gauging the frequency and severity of seizures.
However, self-report has been shown to be inaccurate, which
compromises the extent to which treatments can be optimized or
fully assessed for effectiveness.5
Treatment. Treatment is typically begun after seizures become
manifest and the determination is made that additional seizures
are likely.1 The goals of treatment are to address the underlying
cause, if known, and achieve seizure freedomwithout troublesome
AED-related side effects. Seizure type, epilepsy syndrome, and
demographic variables such as age, gender and concomitant
medications are used to select an initial AED.
Despite the introduction of an unprecedented number of new
AEDs and as well as non-pharmacological treatments over the past
15 years, as many as two out of every three PWE with access to
therapies experience incomplete seizure control or AED-related
side effects that diminish their quality of life. Furthermore,
inexpensive, effective, safe, well-tolerated and culturally accept-
able treatments that can be reliably and continuously distributed
to the tens of millions of PWE impacted by the treatment gap in
resource-poor regions around the world are not readily available.
Other signiﬁcant challenges to the effective treatment of PWE
include our current inability to:
 individualize the selection of AEDs based, for example, on genetic
makeup or biomarkers that indicate the precise pathophysiolog-
ical disturbance(s) underlying seizures, assuming that such
exists
 prevent the development of epilepsy in patients at high risk,
including patients with genetic predisposition and those with
risk factors such as tumours, traumatic brain injury, stroke,
major depression or ADHD6
Persons with epilepsy whose seizures do not respond to the
ﬁrst and second appropriately chosen and dosed AEDs as
monotherapy are candidates for combinations of AEDs. At
present, however, we cannot individualize the selection of AED
combinations for a speciﬁc patient any more than we can
individualize AED monotherapy. Patients with drug-resistant
epilepsy7 may be candidates for adjunctive nonpharmacological
treatments such as resective brain surgery, vagus nerve stimula-
tion, special diets, and stress reduction techniques; as well as for
investigational drugs and brain stimulation devices. However,
other than for resective surgery, we do not have biomarkers that
predict a successful outcome for these interventions. Further-
more, access to care, costs, and other factors may present
insurmountable barriers to obtaining these non-pharmacological
treatments.
Research efforts as well as the advocacy efforts of numerous
epilepsy organisations over the past 60 years have increasingly
focused on patients with drug-resistant seizures, who are at
increased risk of mood disorders, injuries, death and the
potentially disabling psychosocial consequences of epilepsy, but
these remain largely unsolved problems. Yet while the control of
seizures has been the primary objective in the care of PWE and
related research initiatives over the past 60 years, and appropri-
ately so, a large proportion of PWE experience an unsatisfactory
quality of life because of other factors, such as treatment-relatedside effects, cognitive dysfunction, stigma, the post-ictal state, and
psychiatric disorders, including depression and anxiety.8 Available
evidence-based therapeutic options for these non-ictal aspects of
epilepsy are limited and further compounded by inadequate
diagnostic methods as noted earlier.
Many patients with drug-resistant seizures as well as a
signiﬁcant proportion of PWE who achieve seizure freedom have
troublesome dose-related AED side effects or idiosyncratic organ
toxicity, in part because the current approach to treatment is to
administer therapies orally and at dosages and dosing intervals
that maintain constant serum therapeutic levels. As a result,
systemic structures such as bone marrow, liver and skin, as well as
areas of the brain unrelated to seizure control, are continuously
exposed to the potentially toxic effects of AEDs, even though
seizure-suppressing treatments may actually be needed only
intermittently to prevent seizures and directed only to speciﬁc
targets in the brain.
In resource-constrained areas, a large proportion of PWE
receive no evidenced-based treatment. Further compounding this
deplorable situation is that PWE from these regions are often
highly stigmatized.9
Social management. The tremendous progress in the social
management of epilepsy achieved over the past 60 years has made
it possible for more PWE than ever before to live at their full
potential.10 However, epilepsy continues to present unique
challenges to the large majority of PWE and their families,
including uncertainty and fear of having a seizure; limitations on
lifestyle, school, driving and employment; cognitive impairment;
lack of seizure control and treatment-related side effects.11,12
In developed countries, the care of PWE is largely provided by
physicians and allied health personnel in clinics based on an acute
care model. In such settings, the comprehensive needs of PWE and
their families are generally not addressed, in contrast to the more
holistic approach made possible by a chronic care model.13,14 As a
result, issues pertaining to behaviour, mood, medication adher-
ence, schooling, employment, transportation, insurance, exercise,
socialization, and alternative treatments, to name a few, may be
unrecognized or remain unresolved, thereby exacerbating the
underlying issues, increasing stress levels, and further complicat-
ing the control of seizures, comorbidities and AED-related side
effects.
2. What should be the goals of clinical and social management
of epilepsy for the next 60 years?
The scientiﬁc, medical and social advances of the past 60 years
have brought us closer to meeting today’s goals of ‘‘no seizures,
no side effects’’ for PWE who have access to knowledgeable
clinicians and appropriate diagnostic tests and treatments.
Over the next 60 years, the global epilepsy community should
dedicate its efforts to enable all PWE and persons at risk for
developing epilepsy, irrespective of their ethnic background,
ﬁnancial means or where they live, to achieve their full potential,
unburdened by the physical, psychological and social conse-
quences of epilepsy that remain life-limiting to many today,
thereby expanding the goals to ‘‘no seizures, no side effects, no
comorbidities, no stigma’’; in short, no limitations because of
epilepsy.
Making signiﬁcant progress will require the scientiﬁc and lay
epilepsy organisations to work together to pursue collectively
agreed upon benchmarks [http://www.ninds.nih.gov/research/
epilepsyweb/2007_benchmarks.htm]; challenge commonly held
concepts; expand the pre-clinical models of epilepsy; improve
upon the available methods for diagnosis and treatment of
epilepsy and comorbidities; fully delineate and address the root
causes of the global treatment gap; and put into place a
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Fig. 1. ‘‘Ambulatory EEG’’, by Rachna Pettygrove, an artist living with epilepsy.
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stigma.15,16
Increasing knowledge, and changing attitudes and perceptions
about epilepsy. Eliminating stigma and improving access to
appropriate medical care will require a signiﬁcant increase in
the ongoing efforts to provide educational programs for the very
youngest in elementary schools through students at health-related
graduate schools, and to all relevant groups of people, including
PWE, their family members, health professionals, community
leaders, employers, policymakers, teachers, and ﬁrst responders.
Electronic dissemination of information should take advantage of
social networking tools when appropriate. Research should help
deﬁne the best methods for delivering this knowledge to achieve
the desired impact on the attitudes and perceptions of the target
groups.
Establishing new models for the delivery of medical and
psychosocial care. New models of delivering health care to
PWE, facilitated by linkages between patients, care providers,
electronic medical records, and medical devices, for example
wearable technology to detect seizures, should be explored and
compared with current models. Such approaches could include
combining primary and speciality care17; internet-facilitated
remote care for PWE who cannot travel to care providers, as
demonstrated by a recent study for the treatment of depres-
sion18; and partnering with local healers in resource-poor
environments.19
Diagnosis. Given the inaccuracy of self-report for seizure
frequency and severity, and the low speciﬁcity and sensitivity of
diagnostic tests, which even under the best of circumstances
cannot predict with certainty which AED would fully control
seizures, we need new biomarkers for patients presenting after
their ﬁrst possible seizure that conﬁrm the patient will have
further seizures and that provide the basis for an individualized
treatment plan thatwill completely suppress seizureswithout side
effects.20 These biomarkers are unlikely to emerge from a single
laboratory, but rather a massive effort to link together researchers,
clinicians, themajor funding agencies, such asNIH, and industry, as
was done successfully for Alzheimer’s disease [http://www.nih.
gov/news/health/mar2009/nia-17.htm].
Until we have the cure for all forms of epilepsy, those patients
whose seizures cannot be fully controlled may beneﬁt from
technologies that accurately predict the likelihood of an
impending seizure and provide a warning sufﬁciently in advance
of a seizure for the PWE or caregiver to administer an abortive
therapy or take steps to reduce the likelihood of injury.21 Seizure-
prediction and -detection systems can also be coupled with
treatments such as brain stimulation or local drug delivery
in a closed-loop, automated fashion, and also transmit EEG
patterns and other physiological signals to physicians and
electronic medical records as a tool to monitor clinical response
to treatments.22
These technologies and others that improve upon the accuracy
of patient self-report and enhance patient safety or reduce the
impact of seizures should be designed to augment the PWE’s sense
of mastery and self-empowerment and not to inadvertently
contribute to felt or enacted stigma, as anticipated by the painting
shown in Fig. 1.
The diagnostic challenges associated with caring for PWE
who live in resource-constrained environments or far from
medical facilities could be facilitated by internet-based com-
munications as well as portable diagnostic equipment that could
be sent to the patient, such as an EEG recorder with easy-to-
apply electrodes, that would then be mailed back for analysis
after use.
Finally, new techniques are needed to accurately diagnose
the precise underlying cause(s) of cognitive disturbances, suchas memory dysfunction, behavioural and mood disorders, and
dysfunctional social adaptation so that appropriate interventions
can be developed and made available for the care of PWE.23
Treatment. As the pathophysiology of seizures, epileptogen-
esis and drug-resistant epilepsy are further elucidated and
conceptual models advance, novel therapeutic targets will be
identiﬁed and incorporated into new laboratory-based models of
epilepsy. Compounds that interact with these targets and show
beneﬁt in animal models would be candidates for further pre-
clinical and clinical testing to assess their efﬁcacy and safety as
treatments to prevent the development of epilepsy in patients at
high risk and to achieve seizure freedom for newly treated
patients and those with drug-resistant epilepsy. However, the
costs of drug development in epilepsy have signiﬁcantly
escalated. If these trends continue, it will become increasingly
less likely that drugs will be developed principally for the
treatment of epilepsy. Therefore, the epilepsy community should
work together to lower costs of bringing new treatments to the
market, where possible, especially therapies intended for speciﬁc
epilepsy syndromes.
Given the many unmet needs discussed earlier, other goals that
should be pursued over the next 60 years include:
 Empowering PWE to become active partners in managing their
health
 Expanding the access of PWE to epilepsy surgery
 Developing safe and effective behavioural techniques to avoid
and terminate seizures, as well as to reduce stress and the
severity of anxiety and depressive symptoms
 Identifying biomarkers that allow for rational AED use; including
selection of AEDs and dosages and the identiﬁcation of which
patients should be treated after the ﬁrst seizure and which
patients can be safely taken off treatment without seizure
recurrence
 Avoiding the development of interictal mood, behavioural and
psychotic disorders
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epilepsy (SUDEP), status epilepticus, and suicide
 Targeting the precise cause(s) of a patient’s memory and
cognitive problems with effective interventions
 Developing effective treatments for the psychological problems
underlying psychogenic seizures in PWE
 Establishing affordable, culturally acceptable and sustainable
therapies to address the global treatment gap
Best practices for the medical and social management of
epilepsy in resource-constrained areas are under increasing
study and various stages of implementation through large-scale
initiatives such as the WHO/ILAE Global Campaign Against
Epilepsy.24 Generally, these initiatives target the treatment
gap as well as the development of skilled diagnostic and treat-
ment services, the amelioration of stigma, and the dissemina-
tion of information to enhance knowledge and positive
attitudes about epilepsy among key stakeholders, such as
laypersons, teachers, professionals, ﬁrst responders and clergy.
It is critical for these efforts to continue and signiﬁcantly grow
in scope.
The roles of social agencies. As the main societal voice for PWE
and their families, organisations such as Epilepsy Action have
become change agents for improving the quality of life for PWE.
Increasing the public’s awareness about epilepsy; educating all key
stakeholders about epilepsy, and its treatment and consequences;
providing advice and referral, and in some cases, legal representa-
tion; allocating funds for research, particularly regarding the
psychosocial aspects of epilepsy; and working with government
bodies to protect the rights of PWE are all vitally important
functions that need to expand.
The roles of social agencies will be increasingly important over
the next 60 years as the pressure increases to reduce government
healthcare expenditures as a percentage of overall spending and as
more and better organised healthcare agencies vie for limited
government research dollars and public philanthropic support. To
ensure that progress continues to be made in spite of these trends,
professional and lay epilepsy organisations worldwide should
work closely together to ensure that the medical and social
management of epilepsy evolves together with advances in
medical science to achieve a world in which no PWE is
compromised by epilepsy.20
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